Soluble Cytokine Receptors: Basic Immunology and Clinical Applications

References

• Vitetta ES, Fernandez-Botran R, Myers CD, et al. Cellular interactions in the humoral immune response. Adv Immunol 1989; 45: 1–105.
   PubMed Web of Science ®Google Scholar
• Arai K, Lee F, Miyajima A, et al. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 1990; 59: 783–836.
   PubMed Web of Science ®Google Scholar
• Oppenheim JJ, Saklatvala J. Cytokines and their receptors. In: Oppenheim JJ, Rossio J, Gearing AJH, eds. Clinical applications of cytokines: role in pathogen-esis, diagnosis and therapy. pp 3–15. New York: Oxford University Press, 1993.
   Google Scholar
• Abbas AK, Lichtman AH Pober JS. Cellular and molecular immunology. 2nd ed. Philadelphia: Saunders, 1994.
   Google Scholar
• Janeway CA, Travers P. Immunobiology. The immune system in health and disease. London: Current Biology/Garland Publishing, 1996.
   Google Scholar
• Miyajima A, Kitamura T, Harada N, et al. Cytokine receptors and signal trans-duction. Annu Rev Immunol 1992; 10: 295–331.
   PubMed Web of Science ®Google Scholar
• Taga T, Kishimoto T. Cytokine receptors and signal transduction. FASEB J 1993; 6: 3387–3396.
   Web of Science ®Google Scholar
• Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 1995; 13: 369–398.
   PubMed Web of Science ®Google Scholar
• Leonard WJ, O’Shea JJ. Jaks and Stats: biological implications. Annu Rev Immunol 1998; 16: 293–322.
   PubMed Web of Science ®Google Scholar
• Bach EA, Aguet M Schreiber RD. The IFNg receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997; 15: 563–591.
   PubMed Web of Science ®Google Scholar
• Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J 1991; 5: 2567–2574.
   PubMed Web of Science ®Google Scholar
• Arend WP. Inhibiting the effects of cytokines in human diseases. Adv Intern Med 1995; 40: 365–394.
   PubMedGoogle Scholar
• Fernandez-Botran R, Ma Y Chilton, PM. Soluble cytokine receptors: their roles in immunoregulation, disease and therapy. Adv Immunol 1996; 63: 269–336.
   PubMedGoogle Scholar
• Heaney ML, Golde DW. Soluble receptors in human disease. J Leukocyte Biol 1998; 64: 135–146.
   PubMed Web of Science ®Google Scholar
• Aderka, D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cyt Growth Factor Rev 1996; 7: 231–240.
   PubMedGoogle Scholar
• Paul WE. Pleiotropy and redundancy of T cell derived lymphokines in the immune responses. Cell 1989; 57: 521–524.
   PubMed Web of Science ®Google Scholar
• Smith KA. Interleukin-2: inception, impact and implications. Science 1988; 240: 1169–1176.
   PubMed Web of Science ®Google Scholar
• Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253–278.
   PubMed Web of Science ®Google Scholar
• Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991; 77: 1627–1652.
   PubMedGoogle Scholar
• Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411–520.
   PubMed Web of Science ®Google Scholar
• Farrar MA, Schreiber RD. The molecular cell biology of interferon-g and its receptor. Annu Rev Immunol 1993; 11: 571–611.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. The biological properties of interleukin-1. Eur Cyt Network 1994; 5: 517–531.
   PubMed Web of Science ®Google Scholar
• Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-g. Annu Rev Immunol 1997; 15: 749–795.
   PubMed Web of Science ®Google Scholar
• Gately MK, Renzetti LM, Magram J, et al. Interleukin-12/interleukin-12-recep-tor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16: 495–521.
   PubMed Web of Science ®Google Scholar
• Sanderson CJ, Campbell HD Young IG. Molecular and cellular biology of eosinophil differentiation factor (interleukin-5) and its effects on human and mouse B cells. Immunol Rev 1988; 102: 29–50.
   PubMed Web of Science ®Google Scholar
• Schrader JW. The panspecific hemopoietin of activated T lymphocytes (interleukin-3). Annu Rev Immunol 1986; 4: 205–230.
   PubMedGoogle Scholar
• Moore MAS. The clinical use of colony stimulating factors. Annu Rev Immunol 1991; 9: 159–191.
   PubMed Web of Science ®Google Scholar
• Goodwin RG, Lupton S, Schmierer A, et al. Human interleukin-7: molecular cloning and growth factor activity on human and murine B-lineage cells. Proc Natl Acad Sci USA 1989; 86: 302–306.
   PubMed Web of Science ®Google Scholar
• Dayer, JM, Burger D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur Cyt Netw 1994; 5: 563–571.
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348–2357.
   PubMed Web of Science ®Google Scholar
• Muegge K, Durum SK. Cytokines and transcription factors. Cytokine 1990; 2: 1–8.
   PubMedGoogle Scholar
• Caput D, Beutler B Hartog K, et al. Identification of a common nucleotide sequence in the 3' untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 1986; 83: 1670–1674.
   PubMed Web of Science ®Google Scholar
• Black RA, Kronheim SR, Cantrell M, et al. Generation of biologically active interleukin 1-b by proteolytic cleavage of the inactive precursor. J BiolChem 1988; 263: 9437–9442.
   PubMed Web of Science ®Google Scholar
• Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor-a precursor by metalloproteinases. Nature 1994; 370: 555–557.
   PubMed Web of Science ®Google Scholar
• Hemler ME, Breumer MB, McLean JM, et al. Antigenic stimulation regulates the level of expression of interleukin-2 receptors on human T cells. Proc Natl Acad Sci USA 1984; 81: 2172–2175.
   PubMedGoogle Scholar
• Lowenthal JW, Tougue C, MacDonald HR, et al. Antigenic stimulation regulates the expression of IL-2 receptors in a cytolytic T lymphocyte clone. J Immunol 1985; 134: 931–939.
   PubMedGoogle Scholar
• Lowenthal JW, Greene WC. Contrasting interleukin-2 binding properties of the a (p55) and b (p70) protein subunits of the human high-affinity interleukin-2 receptor. J Exp Med 1987; 166: 1156–1161.
   PubMed Web of Science ®Google Scholar
• Wang HM, Smith KA. The interleukin-2 receptor. Functional consequences of its bimolecular structure. J Exp Med 1987; 166: 1055–1069.
   PubMed Web of Science ®Google Scholar
• Ohara J, Paul WE. Up-regulation of interleukin4/B-cell stimulatory factor 1 receptor expression. Proc Natl Acad Sci USA 1988; 85: 8221–8225.
   PubMed Web of Science ®Google Scholar
• Loughnan MS, Nossal GJV. Interleukins 4 and 5 control expression of IL-2 receptor on murine B cells through independent induction of its two chains. Nature 1989; 340: 76–79.
   PubMed Web of Science ®Google Scholar
• Kondo M, Takeshita T, Ishii N, et al. Sharing of the interleukin-2 (IL-2) receptor g chain between receptors for IL-2 and IL-4. Science 1993; 262: 1874–1877.
   PubMed Web of Science ®Google Scholar
• Russell SM, Keegan AD, Harada N, et al. The interleukin-2 receptor g chain is a functional component of the interleukin-4 receptor. Science 1993; 262: 1880–1883.
   PubMed Web of Science ®Google Scholar
• Minami Y, Kondo T, Miyazaki T, et al. The IL-2 receptor complex: its structure, function and target genes. Annu Rev Immunol 1993; 11: 245–267.
   PubMed Web of Science ®Google Scholar
• Sims JE, Gayle MA, Slack JL, et al. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA 1993; 90: 6155–6159.
   PubMed Web of Science ®Google Scholar
• Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993; 261: 472–475.
   PubMed Web of Science ®Google Scholar
• Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63: 1149–1157.
   PubMed Web of Science ®Google Scholar
• Davis S, Aldrich TH, Ip NY, et al. Released form of CNTF receptor a component as a soluble mediator of CNTF responses. Science 1993; 259: 1736–1739.
   PubMed Web of Science ®Google Scholar
• Sato TA, Widmer MB, Finkelman FD, et al. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 1993; 150: 2717–2723.
   PubMed Web of Science ®Google Scholar
• Fernandez-Botran R, Vitetta ES. Evidence that natural murine soluble interleukin 4 receptors may act as transport proteins. J Exp Med 1991; 174: 673–681.
   PubMed Web of Science ®Google Scholar
• Aderka D, Engelmann H, Maor Y, et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323–329.
   PubMed Web of Science ®Google Scholar
• Ma Y, Hurst HE, Fernandez-Botran R. Soluble interleukin-4 receptors as carrier proteins: their effects on the pharmacokinetics of murine IL-4 in vivo. J Pharmacol Exp Ther 1996; 279: 340–350.
   Google Scholar
• Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336–340.
   PubMed Web of Science ®Google Scholar
• Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341–346.
   PubMed Web of Science ®Google Scholar
• Sorg RV, Enczmann J, Sorg U, et al. Rapid and sensitive mRNA phenotyping for interleukins (IL-1 to IL-6) and colony-stimulating factors (G-CSF, M-CSF, and GM-CSF) by reverse transcription and subsequent polymerase chain reaction. Exp Hematol 1991; 19: 882–887.
   PubMed Web of Science ®Google Scholar
• Sorg RV, Enczmann J, Sorg U, et al. Identification of an alternatively spliced transcript of human interleukin-4 lacking the sequence encoded by exon 2. Exp Hematol 1993; 21: 560–563.
   PubMed Web of Science ®Google Scholar
• Brown JM, Muchmore AV Rosenstreich DL. Uromodulin, an immuno-suppres-sive protein derived from pregnancy urine, is an inhibitor of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 9119–9123.
   PubMedGoogle Scholar
• Hession C, Decker JM, Sherblom AP, et al. Uromodulin (Tamm-Horsfall gly-coprotein): a renal ligand for lymphokines. Science 1987; 237: 1479–1484.
   PubMed Web of Science ®Google Scholar
• Borth W, Luger TA. Identification of a2-macroglobulin as a cytokine-binding plasma protein. J Biol Chem 1989; 264: 5818–5825.
   PubMedGoogle Scholar
• Matsuda T, Hirano T, Nagasawa S, et al. Identification of a2-macroglobulin as a carrier protein for IL-6. J Immunol 1989; 142: 148–152.
   PubMed Web of Science ®Google Scholar
• James K. Interactions between cytokines and a2-macroglobulin. Immunol Today 1990; 11: 163–166.
   PubMedGoogle Scholar
• Suzuki H, Kamimura J, Ayabe T, et al. Demonstration of neutralizing autoan-tibodies against IL-1a in sera from patients with rheumatoid arthritis. J Immunol 1990; 145: 2140–2146.
   PubMedGoogle Scholar
• Mae N, Liberato DF, Chizzonite R, et al. Identification of high-affinity anti-IL-1a autoantibodies in normal human serum as an interfering substance in a sensitive enzyme-linked immunosorbent assay for IL-1a. Lymphokine Cytokine Res 1991; 10: 61–68.
   PubMedGoogle Scholar
• Takemura H, Suzuki H, Yoshizaki K, et al. Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum 1992; 35: 940–943.
   PubMedGoogle Scholar
• Hansen MB, Svenson M, Diamant M, et al. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 1993; 5: 72–80.
   PubMedGoogle Scholar
• Jackson RL, Busch SJ Cardin AD. Glycosaminoglycans: molecular properties, protein interactions and role in physiological processes. Physiol Rev 1991; 71: 481–539.
   PubMed Web of Science ®Google Scholar
• Kjellen L, Lindahl A. Proteoglycans-structures and interactions. Annu Rev Biochem 1991; 60: 443–475.
   PubMed Web of Science ®Google Scholar
• Cockwell P, Adams DH Savage COS. Glycosaminoglycans contribute to multiple functions of vascular endothelial cells. Clin Exp Immunol 1996; 104: 1–3.
   PubMedGoogle Scholar
• Tanaka Y, Adams DH Shaw S. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today 1993; 14: 111–115.
   PubMedGoogle Scholar
• Spillman D, Lindahl U. Glycosaminoglycan-protein interactions: a question of specificity. Curr Opin Struct Biol 1994; 4: 677–682.
   Google Scholar
• Roberts R, Gallagher J, Spooncer E, et al. Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature 1988; 332: 376–378.
   PubMed Web of Science ®Google Scholar
• Lortat-Jacob H, Grimaud JA. Interferon-g C-terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-g protect, relax the cytokine and regulate its activity. Cell Mol Biol 1991; 37: 253–260.
   PubMedGoogle Scholar
• Lantz M, Thysell H, Nilsson E, et al. On the binding of tumour necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 1991; 88: 2026–2031.
   PubMed Web of Science ®Google Scholar
• Ramsden L, Rider CC. Selective and differential binding of interleukin (IL)-a, IL-1b, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol 1992; 22: 3027–3031.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Adams DH, Hubscher S, et al. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1b. Nature 1993; 361: 79–82.
   PubMed Web of Science ®Google Scholar
• Finkelmann FD, Katona IM, Urban JF, Jr. et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990; 8: 303–333.
   PubMedGoogle Scholar
• Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172–3177.
   PubMed Web of Science ®Google Scholar
• Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506–512.
   PubMedGoogle Scholar
• Smith CA, Farrah T Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994; 76: 959–962.
   PubMed Web of Science ®Google Scholar
• Davis S, Aldrich TH, Valenzuela DM, et al. The receptor for ciliary neurotrophic factor. Science 1991; 253: 59–63.
   PubMed Web of Science ®Google Scholar
• Rubin LA, Galli F, Greene WC, et al. The molecular basis for the generation of human soluble interleukin-2 receptor. Cytokine 1990; 2: 330–335.
   PubMedGoogle Scholar
• Mosley B, Beckman MP, March CJ, et al. The murine Interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell 1989; 59: 335–348.
   PubMed Web of Science ®Google Scholar
• Wrighton N, Campbell LA, Harada N, et al. The murine interleukin-4 receptor gene: genomic structure, expression and potential for alternative splicing. Growth Factors 1992; 6: 103–118.
   PubMed Web of Science ®Google Scholar
• Tavernier J, Devos R, Cornelis S, et al. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL-5-specific a chain and a b chain shared with the receptor for GM-CSF. Cell 1991; 66: 1175–1184.
   PubMed Web of Science ®Google Scholar
• Horiuchi S, Koyanagi Y, Zhou Y, et al. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol 1994; 24: 1945–1948.
   PubMed Web of Science ®Google Scholar
• Goodwin RG, Friend D, Ziegler SF, et al. Cloning of the human and murine interleukin-7 receptors: Demonstration of a soluble form and homology to a new receptor superfamily. Cell 1990; 60: 941–951.
   PubMed Web of Science ®Google Scholar
• Robb L, Hilton DJ, Wilson TA, et al. Structural analysis of the gene encoding the murine interleukin-11 receptor a-chain and a related locus. J Biol Chem 1996; 271: 13754–13761.
   PubMed Web of Science ®Google Scholar
• Novick D, Cohen B Rubinstein M. The human interferon a/b receptor: characterization and molecular cloning. Cell 1994; 77: 391–400.
   PubMed Web of Science ®Google Scholar
• Brown CB, Beaudry P, Laing TD, et al. In vitro characterization of the human recombinant soluble granulocyte-macrophage colony-stimulating factor receptor. Blood 1995; 85: 1488–1495.
   PubMed Web of Science ®Google Scholar
• Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990; 113: 619–627.
   PubMed Web of Science ®Google Scholar
• Honda M, Yamamoto S, Chang M, et al. Human soluble IL-6-receptor: Its detection and enhanced release by HIV infection. J Immunol 1992; 148: 2175–2180.
   PubMed Web of Science ®Google Scholar
• Chilton PM, Fernandez-Botran R. Production of soluble IL-4 receptors by murine spleen cells is regulated by T cell activation and IL-4. J Immunol 1993; 151: 5907–5917.
   PubMedGoogle Scholar
• Cope AP, Aderka D, Wallach D, et al. Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF. Immunology 1995; 84: 21–30.
   PubMed Web of Science ®Google Scholar
• Symons JA, Eastgate JA Duff GW. A soluble binding protein specific for interleukin 1b is produced by activated mononuclear cells. Cytokine 1990; 2: 190–198.
   PubMedGoogle Scholar
• Leeuwenberg JF, Dentener MA Buurman WA. Lipopolysaccharide LPS-medi-ated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS binding protein, and bactericidal/permeability-increasing protein. J Immunol 1994; 152: 5070–5076.
   PubMed Web of Science ®Google Scholar
• Kuhns DB, Alvord WG Gallin JI. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans. J Infect Dis 1995; 171: 145–152.
   PubMedGoogle Scholar
• Bemelmans MH, Abramowicz D, Gouma DJ, et al. In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice. Effects of pentoxifylline, methylprednisolone, anti-TNF, and anti-IFN-gamma antibodies. J Immunol 1994; 153: 499–506.
   PubMedGoogle Scholar
• Lotze MT, Custer MC, Sharrow SO, et al. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res 1987; 47: 2188–2195.
   PubMed Web of Science ®Google Scholar
• Voss SD, Hank JA, Nobis CA, et al. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother 1989; 29: 261–269.
   PubMed Web of Science ®Google Scholar
• Chilton PM, Fernandez-Botran R. Regulation of the expression of the soluble and membrane forms of the murine IL-4 receptor. Cell Immunol 1997; 180: 104–115.
   PubMedGoogle Scholar
• Lantz M, Malik S, Slevin ML, et al. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990; 2: 402–406.
   PubMedGoogle Scholar
• Fernandez-Botran R, Wynn TA, Hieny S, et al. Linked in vivo expression of soluble interleukin-4 receptor and IL-4 in murine schistosomiasis. Eur J Immunol 1995; 25: 649–656.
   PubMedGoogle Scholar
• Fernandez-Botran R, Chilton PM, Ma Y, et al. Control of the production of soluble interleukin-4 receptors: implications in immunoregulation. J Leuk Biol 1996; 59: 499–504.
   PubMedGoogle Scholar
• Bismuth G, Leclercq L, Duphot M, et al. In vitro induction and expression of interleukin-2 receptor in a cloned T helper cell differentiation model. Cell Immunol 1984; 86: 90–100.
   PubMedGoogle Scholar
• Smith KA, Cantrell D. Interleukin-2 regulates its own receptor. Proc Natl Acad Sci USA 1985; 82: 864–868.
   PubMed Web of Science ®Google Scholar
• Jacques Y, Le Mauff B, Boeffard F, et al. A soluble interleukin-2 receptor produced by a normal alloreactive human T cell clone binds interleukin-2 with low affinity. J Immunol 1987; 139: 2308–2316.
   PubMed Web of Science ®Google Scholar
• Baran D, Korner M Thèze J. Characterization of the soluble murine IL-2R and estimation of its affinity for IL-2. J Immunol 1988; 141: 539–546.
   PubMedGoogle Scholar
• Treiger BF, Leonard WJ, Svetlik P, et al. A secreted form of the human interleukin-2 receptor encoded by an “anchor minus” cDNA. J Immunol 1986; 136: 4099–4105.
   PubMed Web of Science ®Google Scholar
• Kondo N, Kondo S, Shimizu A, et al. A soluble “anchorminus” interleukin-2 receptor suppresses in vitro interleukin 2-mediated immune responses. Immunol Lett 1988; 19: 299–308.
   PubMedGoogle Scholar
• Debets R, Savelkoul HFJ. Cytokine antagonists and their potential therapeutic use. Immunol Today 1994; 15: 455–458.
   PubMedGoogle Scholar
• Gessner A, Rollinghoff M. Soluble IL-4 receptor, potential for therapeutic and prophylactic intervention. Behring Inst Mitt 1994; 95: 35–41.
   Google Scholar
• Maliszewski CR, Sato TA, Davison B, et al. In vivo biological effects of recombinant soluble interleukin-4 receptor. Proc Soc Exp Biol Med 1994; 206: 233–237.
   PubMedGoogle Scholar
• Hale KK, Smith CG, Baker SL, et al. Multifunctional regulation of the biological effects of TNF-a by the soluble type I and type II TNF receptors. Cytokine 1995; 7: 26–38.
   PubMed Web of Science ®Google Scholar
• Mohler KM, Torrance DJ, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548–1561.
   PubMed Web of Science ®Google Scholar
• Finkelman FD, Madden KB, Morris SC, et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol 1993; 151: 1235–1244.
   PubMed Web of Science ®Google Scholar
• May L, Neta R, Moldawer LL, et al. Antibodies chaperone circulating IL-6: paradoxical effects of anti-IL-6 “neutralizing” antibodies in vivo. J Immunol 1994; 151: 3225–3236.
   Google Scholar
• Novick D, Shulman LM, Chen L, et al. Enhancement of interleukin-6 cytostatic effect on human breast carcinoma cells by soluble IL-6-receptor from urine and reversion by monoclonal antibody. Cytokine 1992; 4: 6–11.
   PubMedGoogle Scholar
• Suzuki H, Yasukawa K, Saito T, et al. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol 1993; 23: 1078–1082.
   PubMedGoogle Scholar
• Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993; 90: 11924–11928.
   PubMed Web of Science ®Google Scholar
• Schöbitz B, Pezeshki G, Pohl T, et al. Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J 1995; 9: 659–664.
   PubMed Web of Science ®Google Scholar
• Akira S, Hirano T, Taga T, et al. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J 1990; 4: 2860–2867.
   PubMed Web of Science ®Google Scholar
• Estrov Z, Kurzrock R, Estey E, et al. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 1992; 79: 1938–1945.
   PubMed Web of Science ®Google Scholar
• Van Leenen D, van der Poll T, Levi M, et al. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 1993; 151: 2318–2325.
   PubMed Web of Science ®Google Scholar
• Hart PH, Vitti GF, Burgess DR, et al. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor a, interleukin 1 and prostaglandin E2. Proc Natl Acad Sci USA 1989; 86: 3803–3807.
   PubMed Web of Science ®Google Scholar
• Standiford TJ, Strieter RM, Chensue SW, et al. IL-4 inhibits the expression of IL-8 from stimulated human monocytes. J Immunol 1990; 145: 1435–1439.
   PubMed Web of Science ®Google Scholar
• Moore KW, O’Garra A, de Waal Maleyft R, et al. Interleukin-10. Annu Rev Immunol 1993; 11: 165–190.
   PubMed Web of Science ®Google Scholar
• Jacobs CA, Lynch DH, Roux E, et al. Characterization and pharmacokinetic parameters of recombinant soluble interleukin-4 receptor. Blood 1991; 77: 2396–2403.
   PubMed Web of Science ®Google Scholar
• Jacobs CA, Beckmann MP, Mohler K, et al. Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int Rev Exp Pathol 1993; 34 Pt B: 123–135.
   Google Scholar
• Ozmen L, Gribaudo G, Fountoulakis M, et al. Mouse soluble IFNg receptor as IFNg inhibitor. Distribution, antigenicity, and activity after injection in mice. J Immunol 1993; 150: 2698–2705.
   PubMedGoogle Scholar
• Kürschner C, Garotta G Dembic´ Z. Construction, purification, and characterization of new interferon g (IFNg) inhibitor proteins. J Biol Chem 1992; 267: 9354–9360.
   PubMedGoogle Scholar
• Peschon J, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998; 160: 943–952.
   PubMed Web of Science ®Google Scholar
• Lucas R, Lou J, Morel DR, et al. TNF receptors in the microvascular pathology of acute respiratory distress syndrome and cerebral malaria. J Leukocyte Biol 1997; 61: 551–558.
   PubMed Web of Science ®Google Scholar
• Seckinger P, Isaaz S Dayer JM. A human inhibitor of tumor necrosis factor a. J Exp Med 1988; 167: 1511–1516.
   PubMed Web of Science ®Google Scholar
• Engelmann HD, Aderka D, Rubinstein M, et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264: 11974–11980.
   PubMed Web of Science ®Google Scholar
• Olsson I, Lantz M, Nilsson E, et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989; 42: 270–275.
   PubMed Web of Science ®Google Scholar
• Gatanaga T, Lentz R, Masunaka I, et al. Identification of TNF-LT blocking factor(s)in the serum and ultrafiltrates of human cancer patients. Lymphokine Res 1990; 9: 225–229.
   PubMedGoogle Scholar
• Seckinger P, Zhang JH, Hauptmann B, et al. Characterization of a tumor necrosis factor a (TNF-a) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 1990; 87: 5188–5192.
   PubMed Web of Science ®Google Scholar
• Nophar Y, Kemper O, Brakebusch C, et al. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990; 9: 3269–3278.
   PubMed Web of Science ®Google Scholar
• Steinshamn S, Bemelmans MH, Buurman WA, et al. Granulocytopenia reduces the release of soluble TNF receptor p75 in endotoxin-stimulated mice: a possible mechanism of enhanced TNF activity. Cytokine 1995; 7: 50–56.
   PubMed Web of Science ®Google Scholar
• Mylius-Spencker H, Winzen R, Resch K, et al. Regulation of the expression of transmembrane and soluble 75 kDa tumor necrosis factor receptors by inter-feron-g and granulocyte-macrophage colony stimulating factor involves tran-scriptional activation. Eur Cytokine Netw 1997; 8: 351–358.
   PubMedGoogle Scholar
• Evans TJ, Moyes D, Carpenter A, et al. Protective effect of 55 kD but not 75 kD soluble TNF receptor-IgG fusion proteins in an animal model of Gram-negative sepsis. J Exp Med 1994; 180: 2173–2179.
   PubMed Web of Science ®Google Scholar
• Suter PM, Suter S, Girardin E, et al. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992; 145: 1016–1022.
   PubMed Web of Science ®Google Scholar
• Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160–1169.
   PubMed Web of Science ®Google Scholar
• Roux-Lombard P, Punzi L, Hasler F, et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993; 36: 485–489.
   PubMed Web of Science ®Google Scholar
• Barrera P, Boerbooms AMT, Janssen EM, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor a, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993; 36: 1070–1079.
   PubMed Web of Science ®Google Scholar
• Gattorno M, Picco P, Buoncompagni A, et al. Serum p55 and p75 tumor necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. Ann Rheum Dis 1996; 55: 243–247.
   PubMed Web of Science ®Google Scholar
• Aderka D, Wysenbeek A, Engelmann H, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1111–1120.
   PubMedGoogle Scholar
• Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997; 24: 303–308.
   PubMed Web of Science ®Google Scholar
• Mangge H, Kenzian H, Gallisti S, et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995; 38: 211–220.
   PubMed Web of Science ®Google Scholar
• Froon AH, Bemelmans MH, Greve TW, et al. Increased concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med 1994; 22: 803–809.
   PubMed Web of Science ®Google Scholar
• Kern P, Hemmer CJ, Gallati H, et al. Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J Infect Dis 1992; 166: 930–934.
   PubMed Web of Science ®Google Scholar
• Deloron P, Roux-Lombard P, Ringwald P, et al. Plasma levels of TNF-a soluble receptors correlate with outcome in human falciparum malaria. Eur Cytokine Netw 1994; 5: 331–336.
   PubMedGoogle Scholar
• Sarthou JL, Angel G, Aribot G, et al. Prognostic value of anti-Plasmodium falciparum-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria. Infect Immun 1997; 65: 3271–3276.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Tilz GP, Lueger A, et al. Elevated plasma levels of soluble tumor necrosis factor receptor (sTNFRp60) reflect severity of acute pancreatitis. Intensive Care Med 1997; 23: 841–848.
   PubMed Web of Science ®Google Scholar
• Keil M, Pec MK, Schenn G, et al. Value of serum soluble tumor necrosis factor concentrations in the diagnosis and prognosis of renal graft rejection. Nephrol Dial Transplant 1994; 9: 815–819.
   PubMed Web of Science ®Google Scholar
• Aderka D, Engelmann H, Hornik V, et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991; 51: 5602–5607.
   PubMed Web of Science ®Google Scholar
• Aderka, D, Granot V, Levavi H, et al. The value of soluble TNF receptors in predicting relapse of ovarian carcinoma. Eur Cytokine Netw 1994; 5: 217.
   Google Scholar
• Jablonska E, Pietruska Z. Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients. Arch Immunol Ther Exp 1997; 45: 449–453.
   PubMedGoogle Scholar
• Fossa SD, Aamdal S, Naume B, et al. Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-a combination therapy. Acta Oncol 1995; 34: 599–603.
   PubMed Web of Science ®Google Scholar
• Warzocha K, Salles G, Bienvenu J, et al. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol 1997; 15: 499–508.
   PubMed Web of Science ®Google Scholar
• Kalinkovich A, Engelmann H, Burstein HR, et al. Elevated serum levels of soluble tumor necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Med 1992; 89: 351–355.
   Google Scholar
• Hober D, Benyoucef S, Delannoy AS, et al. High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients. Infection 1996; 24: 213–217.
   PubMedGoogle Scholar
• Godfried MH, van der Poll T, Mulder JW, et al. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. J Acquired Imm Def Synd & Human Retrovirol 1995; 10: 531–539.
   PubMedGoogle Scholar
• Howard OM, Clouse KA, Smith C, et al. Soluble tumor necrosis factor receptor: inhibition of human immunodeficiency virus activation. Proc Natl Acad Sci USA 1993; 90: 2335–2339.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Marsters SA, Capon DJ, et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 1991; 88: 10535–10539.
   PubMed Web of Science ®Google Scholar
• Lesslauer W, Tabuchi H, Gentz R, et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991; 21: 2883–2886.
   PubMed Web of Science ®Google Scholar
• Fisher CJ, Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The soluble TNF receptor sepsis study group. N Engl J Med 1996; 334: 1697–1702.
   PubMed Web of Science ®Google Scholar
• Leighton A, Abraham E, Glauser M, et al. TNF-R55-IgG1 (Ro-45-2081) in severe sepsis shock: Rationale for design of the phase III protocol. Eur Cytokine Netw 1996; 7: 282.
   Google Scholar
• Piguet PF, Grau GE, Vesin C, et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992; 77: 510–514.
   PubMed Web of Science ®Google Scholar
• Wooley PH, Dutcher J, Widmer MB, et al. Influence of recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151: 6602–6607.
   PubMed Web of Science ®Google Scholar
• Klinkert WEF, Kojima K, Lesslauer W, et al. TNF-a receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol 1997; 72: 163–168.
   PubMed Web of Science ®Google Scholar
• Renzetti LM, Gater PR. Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways. Inflamm Res 1997; 46(Suppl 2)</b>: S143–144.
   Google Scholar
• Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141–147.
   PubMed Web of Science ®Google Scholar
• Murray KM, Dahl SL. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother 1997; 31: 1335–1338.
   PubMedGoogle Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recom-binant tumor necrosis factor receptor: Fcfusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–259.
   PubMed Web of Science ®Google Scholar
• Symons JA, Eastgate JA Duff GW. Purification and characterization of a novel soluble receptor for interleukin 1. J Exp Med 1991; 174: 1251–1254.
   PubMed Web of Science ®Google Scholar
• Svenson M, Hansen MB, Heegaard P, et al. Specific binding of interleukin 1 (IL-1)b and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine 1993; 5: 427–435.
   PubMed Web of Science ®Google Scholar
• Dower SK, Wignall JM, Schooley K, et al. Retention of ligand binding activity by the extracellular domain of the IL-1 receptor. J Immunol 1991; 142: 4314–4320.
   Web of Science ®Google Scholar
• Fanslow WC, Sims JE, Sassenfeld H, et al. Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science 1990; 248: 739–742.
   PubMed Web of Science ®Google Scholar
• Jacobs CA, Baker PE, Roux ER, et al. Experimental autoimmune encephalomy-elitis is exacerbated by IL-1a and suppressed by soluble IL-1 receptor. J Immunol 1991; 148: 2983–2989.
   Google Scholar
• Mullarkey MF, Leiferman KM, Peters MS, et al. Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor. J Immunol 1994; 152: 2033–2041.
   PubMed Web of Science ®Google Scholar
• Eastgate JA, Symons JA Duff GW. Identification of an interleukin-1b binding protein in human plasma. FEBS Lett. 1990; 260: 213–216.
   PubMedGoogle Scholar
• Symons JA, Young PR Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1b precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 1995; 92: 1714–1718.
   PubMed Web of Science ®Google Scholar
• Burger D, Chicheportiche R, Giri JG, et al. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995; 96: 38–41.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Boney RS. Use of a soluble interleukin-1 receptor to inhibit ocular inflammation. Curr Eye Res 1991; 10: 1137–1139.
   PubMed Web of Science ®Google Scholar
• Ulich TR, Yi ES, Yin S, et al. Intratracheal administration of endotoxin and cytokines. VII. The soluble interleukin-1 receptor and the soluble tumor necrosis factor receptor II (p80) inhibit acute inflammation. Clin Immunol Immunopathol 1994; 72: 137–140.
   PubMedGoogle Scholar
• Peters M, Schirmacher P, Goldschmitt J, et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med 1997; 185: 755–766.
   PubMed Web of Science ®Google Scholar
• Mullberg, J, Durie FH, Otten-Evans C, et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995; 5198–5205.
   Google Scholar
• Gallea-Robache S, Morand V, Millet S, et al. A metalloprotease inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine 1997; 9: 340–346.
   PubMed Web of Science ®Google Scholar
• Mullberg J, Schooltink H, Stoyan T, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993; 23: 473–480.
   PubMed Web of Science ®Google Scholar
• Lust JA, Jelinek DF, Donovan KA, et al. Sequence, expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R). Curr Top Microbiol Immunol 1995; 194: 199–206.
   PubMedGoogle Scholar
• Korholz D, Nussbaum P, Pafferath B, et al. Activation of protein kinase C induces de novo synthesis of the soluble interleukin-6 receptor in human B cells. Scand J Immunol 1994; 40: 515–520.
   PubMedGoogle Scholar
• Novick D, Engelmann H, Wallach D, et al. Soluble cytokine receptors are present in normal human urine. J Exp Med 1989; 170: 1409–1414.
   PubMed Web of Science ®Google Scholar
• Frieling JT, Sauerwein RW, Wijdenes J, et al. Soluble interleukin-6 receptor in biological fluids from human origin. Cytokine 1994; 6: 376–381.
   PubMedGoogle Scholar
• Mihara M, Moriya Y, Kishimoto T, et al. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 1995; 34: 321–325.
   PubMedGoogle Scholar
• Mitsuyama K, Toyonaga A, Sasaki E, et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995; 36: 45–49.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Kohno N, Hirasawa Y, et al. Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. Clin Exp Immunol 1995; 100: 325–329.
   PubMed Web of Science ®Google Scholar
• Jakobsen PH, McKay V, Morris-Jones SD, et al. Increased concentrations of interleukin-6 and interleukin-1 receptor antagonist and decreased concentrations of beta-2-glycoprotein I in Gambian children with cerebral malaria. Infect Immun 1994; 62: 4374–4379.
   PubMedGoogle Scholar
• Gaillard JP, Bataille R, Brailly H, et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 1993; 23: 820–824.
   PubMed Web of Science ®Google Scholar
• Gaillard JP, Liautard J, Klein B, et al. Major role of the soluble interleukin-6/ interleukin-6 receptor complex in the proliferation of interleukin-6-dependent human myeloma cell lines. Eur J Immunol 1997; 27: 3332–3340.
   PubMed Web of Science ®Google Scholar
• Greipp PR. Prognosis in myeloma. Mayo Clin Proc 1994; 69: 895–902.
   PubMedGoogle Scholar
• Frieling JT, van Deuren M, Wijdenes J, et al. Circulating interleukin-6 receptor in patients with sepsis syndrome. J Infect Dis 1995; 171: 469–472.
   PubMed Web of Science ®Google Scholar
• Maes M, Meltzer HY Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994; 89: 346–351.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Massa M, Pignatti P, et al. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994; 93: 2114–2119.
   PubMed Web of Science ®Google Scholar
• Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82: 1120–1126.
   PubMed Web of Science ®Google Scholar
• Osawa H, Josimovic-Alasevic O Diamantstein T. Interleukin-2 receptors are released by cells in vitro and in vivo. I. Detection of soluble interleukin-2 receptors in cell culture supernatants and in the serum of mice by immunoradiometric assay. Eur J Immunol 1986; 16: 467–469.
   PubMed Web of Science ®Google Scholar
• Wagner DK, York-Jolley J, Malek TR, et al. Antigen-specific murine T cell clones produce soluble interleukin-2 receptor on stimulation with specific antigen. J Immunol 1986; 137: 592–596.
   PubMedGoogle Scholar
• Symons JA, Wood NC, Di Giovine F, et al. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol 1988; 141: 2612–2618.
   PubMed Web of Science ®Google Scholar
• Barral-Netto M, Barral A, Santos SB, et al. Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol 1991; 147: 281–284.
   PubMed Web of Science ®Google Scholar
• Richards JM, Mick R, Latta JM, et al. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood 1990; 76: 1941–1945.
   PubMed Web of Science ®Google Scholar
• Ambrosetti A, Nadali G, Vinante F, et al. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome. Cancer 1993; 72: 201–206.
   PubMed Web of Science ®Google Scholar
• Kamihira S, Atogami S, Sohda H, et al. Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 1994; 73: 2753–2758.
   PubMed Web of Science ®Google Scholar
• Prince HE, Kleinman S Williams AE. Soluble IL-2 receptor levels in serum from blood donors seropositive for HIV. J Immunol 1988; 140: 1139–1141.
   PubMedGoogle Scholar
• Honda M, Kitamura K, Matsuda K, et al. Soluble IL-2 receptor in AIDS. Correlation of its serum level with the classification of HIV-induced diseases and its characterization. J Immunol 1989; 142: 4248–4255.
   PubMedGoogle Scholar
• Semenzato G, Bambara LM, Biasi D, et al. Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol 1988; 8: 447–452.
   PubMedGoogle Scholar
• Tokano Y, Murashima A, Takasaki Y, et al. Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 803–809.
   PubMed Web of Science ®Google Scholar
• Josimovic-Alasevic O, Feldmeier H, Zwingenberger K, et al. Interleukin 2 receptor in patients with localized and systemic parasitic diseases. Clin Exp Immunol 1988; 72: 249–254.
   PubMedGoogle Scholar
• Brown AE, Rieder T Webster HK. Prolonged elevations of soluble interleukin-2 receptors in tuberculosis. Am Rev Respir Dis 1989; 139: 1036–1038.
   PubMed Web of Science ®Google Scholar
• Muller C, Knoflach P Zielinski CC. Soluble interleukin 2 receptor in acute viral hepatitis and chronic liver disease. Hepatology 1989; 10: 928–932.
   PubMed Web of Science ®Google Scholar
• Perkins JD, Nelson DL, Rakela J, et al. Soluble interleukin 2 receptor level in liver allograft recipients: an indicator of rejection. Transplantation 1989; 47: 77–81.
   PubMed Web of Science ®Google Scholar
• Bock GH, Neu L, Long C, et al. An assessment of serum and urine soluble interleukin-2 receptor concentrations during renal transplant rejection. Am J Kidney Dis 1994; 23: 421–426.
   PubMedGoogle Scholar
• Honda M, Kitamura K, Takeshita T, et al. Identification of a soluble IL-2 receptor b-chain from human lymphoid cell line cells. J Immunol 1990; 145: 4131–4135.
   PubMed Web of Science ®Google Scholar
• Harada N, Castle BE, Gorman DM, et al. Expression cloning of a cDNA encoding the murine interleukin 4 receptor based on ligand binding. Proc Natl Acad Sci USA 1990; 87: 857–861.
   PubMed Web of Science ®Google Scholar
• Idzerda RL, March CJ, Mosley B, et al. Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J Exp Med 1990; 171: 861–873.
   PubMed Web of Science ®Google Scholar
• Blum H, Wolf M, Enssle K, et al. Two distinct stimulus-dependent pathways lead to production of soluble murine interleukin-4 receptor. J Immunol 1996; 157: 1846–1853.
   PubMedGoogle Scholar
• Konig B, Neuber K Konig W. Responsiveness of peripheral blood mononuclear cells from normal and atopic donors to microbial superantigens. Int Arch Allergy Immunol 1995; 106: 124–133.
   PubMedGoogle Scholar
• Maliszewski CR, Sato TA, VandenBos T, et al. Cytokine receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-4 and IL-4 induced B cell activities in vitro. J Immunol 1990; 144: 3028–3033.
   PubMedGoogle Scholar
• Fanslow WC, Clifford KN, Park LS, et al. Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J Immunol 1991; 147: 535–540.
   PubMed Web of Science ®Google Scholar
• Gessner A, Schroppel K, Will A, et al. Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous leishmaniasis. Infect Immunol 1994; 62: 4112–4117.
   PubMed Web of Science ®Google Scholar
• Puccetti P, Mencacci A, Cenci E, et al. Cure of murine candidiasis by recombi-nant soluble interleukin-4 receptor. J Infect Dis 1994; 169: 1325–1331.
   PubMedGoogle Scholar
• Garrone P, Djossou O, Galizzi JP, et al. A recombinant extracellular domain of the human interleukin 4 receptor inhibits the biological effects of interleukin 4 on T and B lymphocytes. Eur J Immunol 1991; 21: 1365–1369.
   PubMed Web of Science ®Google Scholar
• Mita SA, Tominaga A, Hitoshi Y, et al. Characterization of high-affinity receptors for interleukin 5 on interleukin 5-dependent cell lines. Proc Natl Acad Sci USA 1989; 86: 2311–2315.
   PubMed Web of Science ®Google Scholar
• Takaki S, Tominaga A, Hitoshi Y, et al. Molecular cloning and expression of the murine interleukin-5 receptor. EMBO J 1990; 9: 4367–4374.
   PubMed Web of Science ®Google Scholar
• Yasruel Z, Humbert M, Kotsimbos TC, et al. Membrane bound and soluble a IL-5 receptor mRNA in the bronchial mucosa of atopic and nonatopic asthmatics. Am J Resp Crit Care Med 1997; 155: 1413–1418.
   PubMed Web of Science ®Google Scholar
• Pestka S, Langer JA, Zoon KC, et al. Interferons and their actions. Annu Rev Biochem 1987; 56: 727–777.
   PubMed Web of Science ®Google Scholar
• Branca AA, Baglioni C. Evidence that type I and II interferons have different receptors. Nature 1981; 294: 768–770.
   PubMed Web of Science ®Google Scholar
• Orchansky P, Novick D Rubinstein M. Type I and type II interferon receptors. J Interferon Res 1984; 4: 275–282.
   PubMedGoogle Scholar
• Novick D, Cohen B Rubinstein M. Soluble interferon-a receptor molecules are present in body fluids. FEBS Lett 1992; 314: 445–448.
   PubMed Web of Science ®Google Scholar
• Ozmen L, Fountoulakis M, Gentz R, et al. Immunomodulation with soluble IFNg receptor: preliminary study. Int Rev Exp Pathol 1993; 34 Pt B: 137–147.
   Google Scholar
• Ozmen L, Roman D, Fountoulakis M, et al. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble inter-feron-g receptor inhibits the onset of glomerulonephritis. Eur J Immunol 1995; 25: 6–12.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor g chain: a functional component of the interleukin-7 receptor. Science 1993; 262: 1877–1880.
   PubMed Web of Science ®Google Scholar
• Clark SC, Karmen R. The human hematopoietic colony-stimulating factors. Science 1987; 236: 1229–1237.
   PubMed Web of Science ®Google Scholar
• Kitamura T, Sato N, Arai K, et al. Expression cloning of the human IL-3 receptor cDNA reveals a shared b subunit for the human IL-3 and GM-CSF receptors. Cell 1991; 66: 1165–1174.
   PubMed Web of Science ®Google Scholar
• Raines MA, Liu L, Quan SG, et al. Identification and molecular cloning of a soluble human granulocyte-macrophage colony-stimulating factor receptor. Proc Natl Acad Sci USA 1991; 88: 8203–8207.
   PubMed Web of Science ®Google Scholar